<DOC>
	<DOCNO>NCT02292186</DOCNO>
	<brief_summary>The purpose study evaluate safety clinical activity long-term dosing revusiran ( ALN-TTRSC ) . Dosing discontinue ; patient followed-up safety .</brief_summary>
	<brief_title>A Extension Study Evaluate Revusiran ( ALN-TTRSC ) Patients With Transthyretin ( TTR ) Cardiac Amyloidosis</brief_title>
	<detailed_description />
	<mesh_term>Amyloidosis</mesh_term>
	<criteria>Subjects previously receive tolerated revusiran ( ALNTTRSC ) ALNTTRSC002 study Adequate liver function Not Pregnant nursing Inadequate renal function Uncontrolled hypertension , ischemic heart disease clinically significant cardiac arrhythmia Untreated hypo hyperthyroidism Prior major organ transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Cardiomyopathy</keyword>
	<keyword>Heart Failure</keyword>
	<keyword>FAC</keyword>
	<keyword>Amyloid</keyword>
	<keyword>Transthyretin</keyword>
	<keyword>TTR</keyword>
	<keyword>RNAi therapeutic</keyword>
</DOC>